- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Cancer, Poorly Differentiated Neuroendocrine Carcinomas, Homologous Recombination Deficient-Positive Malignancies Agnostic
- Interventions
- Lurbinectedin
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 17
- States / cities
- Stanford, California • Norwich, Connecticut • Fort Myers, Florida + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–42
of 18
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract
- Interventions
- Lurbinectedin, Avelumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Docetaxel, Gemcitabine, Lurbinectedin (PM01183)
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Small Cell Lung Cancer
- Interventions
- ABBV-706, Topotecan, Lurbinectedin, Amrubicin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 27 more
- Conditions
- Major Advanced Solid Tumors Other Than Colorectal
- Interventions
- PM01183
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Chicago, Illinois
- Conditions
- ADVANCED SOLID TUMORS
- Interventions
- PM01183
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma
- Interventions
- Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride, Lurbinectedin
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
- Interventions
- Lurbinectedin
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Iowa City, Iowa • Boston, Massachusetts + 3 more
- Conditions
- Ovarian Cancer
- Interventions
- Paclitaxel, Bevacizumab, Lurbinectedin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Lurbinectedin, Durvalumab
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 1 more
- Conditions
- Small-cell Lung Cancer
- Interventions
- Lurbinectedin (PM01183), Doxorubicin (DOX), Cyclophosphamide (CTX), Vincristine (VCR), Topotecan
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Fullerton, California + 26 more
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 23
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 19 more
- Conditions
- Leiomyosarcoma
- Interventions
- Lurbinectedin, Doxorubicin
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Lurbinectedin, Palliative Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Lung Cancer, Small-cell Lung Cancer
- Interventions
- Trilaciclib, Lurbinectedin
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Chapel Hill, North Carolina
- Conditions
- Advanced Soft-tissue Sarcoma
- Interventions
- Lurbinectedin
- Drug
- Lead sponsor
- ERLINDA M GORDON
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Solid Tumors
- Interventions
- lurbinectedin (PM01183)
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- Up to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Aurora, Colorado • Boston, Massachusetts + 2 more
- Conditions
- Small-Cell Lung Cancer
- Interventions
- Atezolizumab, Lurbinectedin, Carboplatin, Etoposide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 12
- States / cities
- Marietta, Georgia • Peoria, Illinois • Scarborough, Maine + 9 more